RLAY

Relay Therapeutics (RLAY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Earnings

Relay Therapeutics Sees Phase 3 Breast Cancer Trial Filling By Mid-2027, A Year Ahead Of Benchmarks

The biotech's third-quarter net loss widened to $81.7 million, and it says $848.6 million in cash lasts into 2029.

SEC Filings

Relay Therapeutics Pays $1.5 Million To Walk Away From A Cambridge Lab Lease, Taking A $4.5 Million Hit

The drug developer booked a $4.5 million lease-exit cost and added a $4.8 million license obligation as headcount rose to 218.